PROSE研究:欧洲不同地区斑块状银屑病患者需求与司库奇尤单抗治疗满意度差异
PROSE研究为52周开放标签前瞻性非随机分层多中心研究,覆盖16个欧洲国家,按地区二次分析斑块状银屑病患者基线疾病负担、需求及司库奇尤单抗治疗52周后的获益与满意度。结果显示基线DLQI损害东欧高于北欧和西欧(F=5.5,P<0.001),患者需求地区差异明显,52周时东欧患者报告更多获益,北欧患者总体满意度更高。
要点
- 东欧患者基线DLQI损害高于北欧和西欧,但临床意义不确定
- 各地区患者需求侧重点不同:西欧重身体损害,东欧重社会损害,南欧重治疗相关损害
- 52周时东欧患者司库奇尤单抗获益更多,北欧患者总体治疗满意度更高
核心结论
- 欧洲不同地区斑块状银屑病患者的基线需求及司库奇尤单抗治疗满意度存在差异,可能与医疗体系、社会经济状况和基础设施可及性不同有关。
- 以患者为中心的治疗方法可能满足患者需求并最大化治疗满意度。
研究设计与样本
- PROSE为开放标签、前瞻性、非随机、分层多中心研究,司库奇尤单抗治疗52周,覆盖16个欧洲国家。
- 本研究为PROSE数据的按欧洲地区二次分析,比较基线疾病负担与患者需求,及治疗52周后临床改善、患者报告获益与满意度。
主要发现
- 基线DLQI损害东欧为15.4±7.1,高于北欧的13.3±6.7和西欧的13.6±6.9,差异有统计学意义(F检验=5.5,P<0.001),但临床意义不确定。
- 基线PASI各地区间无显著差异(F检验=1.6)。
- 患者需求问卷显示地区差异明显:西欧更关注减少身体损害(对比南欧/东欧),东欧更关注减少社会损害(对比北欧/西欧),南欧更关注减少治疗相关损害(对比北欧/西欧)。
- 第52周时,东欧患者报告司库奇尤单抗治疗获益更多(对比西欧/南欧),北欧患者报告总体治疗满意度更高(对比南欧)。
临床怎么用
- 临床中应关注不同地区银屑病患者的个体化需求差异,采取以患者为中心的治疗策略。
- 评估治疗满意度时需考虑患者所在地区的医疗体系和社会经济背景差异。
局限性
- 原文未报告具体局限性内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Cross-cultural differences in healthcare policies and patient-physician communication may influence the quality of care and patients' perceived benefits and satisfaction with psoriasis treatment. OBJECTIVES: To compare the disease burden and patient needs at baseline, and patient benefits and satisfaction with secukinumab treatment across Europe. METHODS: PROSE was an open-label, prospective, non-randomized, stratified multicentre study of 52 weeks of secukinumab treatment, in 16 European countries. Secondary analysis of the PROSE study data by European regions was performed to identify cross-cultural differences in disease burden and patient needs at baseline, and in clinical improvement, patient-reported treatment benefits and satisfaction at 52 weeks post-treatment. RESULTS: At baseline, Dermatology Life Quality Index impairment was reported to be greater in patients from Eastern Europe (EE: 15.4 ± 7.1) vs. Northern Europe (NE: 13.3 ± 6.7) and Western Europe (WE: 13.6 ± 6.9), but while differences were statistically significant (F-test = 5.5, P < 0.001), their clinical significance is uncertain. There were no significant differences between regions in Psoriasis Area and Severity Index at baseline (F-test = 1.6). There were considerable differences in patients' needs (Patient Need Questionnaire) between geographical regions, with WE focused more on reducing physical impairment [vs. Southern Europe (SE)/EE], EE on reducing social impairment (vs. NE/WE) and SE on reducing impairment due to therapy (vs. NE/WE). At Week 52, patients from EE reported more benefits (Patient Benefit Index) with secukinumab treatment (vs. WE/SE), while patients from NE reported higher global treatment satisfaction (vs. SE). CONCLUSIONS: Differences in patients' needs and treatment satisfaction across Europe are likely a result of diverse medical systems, socio-economic status and infrastructural access. A patient-centred approach to treating psoriasis may fulfil patient needs and maximize treatment satisfaction. (NCT02752776).
引用
- da Silva N, Sommer R, Ortmann CE, et al. Secukinumab effects on disease burden, patient needs and benefits, and treatment satisfaction in patients with plaque psoriasis across European regions: patient perspective data from the PROSE study. J Eur Acad Dermatol Venereol. 2021. PMID: 34273904. doi:10.1111/jdv.17525
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。